WO1997038708A1 - Modulating epithelial-mesenchymal interactions - Google Patents
Modulating epithelial-mesenchymal interactions Download PDFInfo
- Publication number
- WO1997038708A1 WO1997038708A1 PCT/US1997/006309 US9706309W WO9738708A1 WO 1997038708 A1 WO1997038708 A1 WO 1997038708A1 US 9706309 W US9706309 W US 9706309W WO 9738708 A1 WO9738708 A1 WO 9738708A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fgf
- activity
- polypeptide
- fgfr
- interaction
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Definitions
- Heterotypic and heterochronic recombinations of ectodermal and mesodermal components of skins indicate that the formation of the placodes is determined by mesodermal signals. Dermal signals also determine whether scales or feathers will develop, and, if feathers develop, their arrangement in a precise hexagonal pattern. The placodes in turn provide a signal which results in the formation of dermal condensations immediately beneath the placode (Sengel, P. Morphogenesis of Skin. Cambridge University Press, Cambridge, England (1976)). In feather forming regions, continued reciprocal interactions between the cells of the dermal condensation formation and those of the epidermal placode of each individual feather germ result in the outgrowth of the feather germ which at first is radially symmetrical and subsequently grows in a posterior direction.
- the anteroposterior direction of the outgrowth of the feather is determined by the ectoderm (Novel, G.J., Embryol. Exp. Morph. 30:605-633 (1973)).
- ectoderm Novel, G.J., Embryol. Exp. Morph. 30:605-633 (1973)
- cell adhesion molecules, extracellular matrix molecules, and transcription factors may be involved in skin morphogenesis (Chuong, C-M., BioEssays 15:513-552 (1993), Noveen, A., Jiang, T-X, Ting-Berreth. S.A. and Chuong, C-M., J. Invest. Derm. 104:711-719 (1995)).
- no specific molecular mechanisms have been identified to date.
- the invention features, a method of modulating an epidermal-dermal interaction, or a process or product that results from an epidermal-dermal interaction.
- Such interactions include, e.g., placode formation, dermal condensation formation, FGFR-1 induction, or the development of a cutaneous appendage, e.g., a hair, a scale, or a feather.
- the method includes: modulating, e.g., promoting or inhibiting, FGF-2 activity in one or both of the dermis and epidermis. In preferred embodiments FGF-2 activity is promoted.
- FGF-2 activity can be promoted, e.g., by administration of exogenous FGF-2 or a fragment thereof, or a peptide or non-peptide analog thereof.
- FGF-2 activity can also be promoted by administering a nucleic acid which encodes FGF-2 or a fragment thereof, or a peptide analog thereof, or by promoting endogenous FGF-2 activity. In preferred embodiments FGF-2 activity is inhibited.
- FGF-2 activity can be inhibited, e.g., by: administration of an FGF-2 binding molecule, e.g., an anti-FGF-2 antibody or FGF2-binding fragment thereof, or an FGF2-binding fragment of the FGF-2 receptor; administering a compound which inhibits, e.g., competitively or noncompetitively, the binding of FGF-2 to its receptor, e.g., a fragment of FGF-2 which binds the receptor but which lacks biological, e.g., signal transduction, activity, a peptide or non-peptide analog or a small molecule mimic of FGF-2 which binds the receptor but which lacks biological, e.g., signal transduction, activity; administering a nucleic acid which encodes an antisense molecule which inhibits FGF-2 expression.
- an FGF-2 binding molecule e.g., an anti-FGF-2 antibody or FGF2-binding fragment thereof, or an FGF2-binding fragment of the FGF-2 receptor
- the method is practiced in vivo and the subject is a vertebrate, e.g., a bird, or a mammal, e.g., a rodent, e.g., a mouse or a rat, or a primate, e.g., a nonhuman primate or a human.
- the subject is other than a bird, a rodent, e.g., a mouse or a rat, or a nonhuman primate.
- the method is performed in vivo and: the subject is wild type for one or more loci which condition the development of cutaneous appendages, e.g., the subject is wildtype for the scaleless locus; the subject is heterozygous, hemizygous, or homozygous, for a mutation at one or more loci which condition the development of cutaneous appendages, e.g., the subject carries one or more mutant alleles of the scaleless locus; the subject is a transgenic animal which is heterozygous, hemizygous, or homozygous, for a mutation at one or more loci which condition " the development of cutaneous appendages, e.g., the subject carries one or more mutant alleles of the scaleless locus.
- the method is practiced in vitro, e.g., on a tissue or cell, e.g., a cultured cell.
- a compound which modulates FGF-2 activity is administered at least once and preferably at least 2, 4, or 10 times.
- the period between administrations can be more than 2, 4, 10 or 30 days but less than 1 year.
- FGF-2 activity is modulated, e.g., increased or decreased, in the dermis.
- one or both of the dermis or epidermis is: fetal dermis or epidermis; adult dermis or epidermis.
- the invention features, a method of modulating the development of a cutaneous appendage, e.g., a hair, a scale, or a feather. The method includes: modulating, e.g., promoting or inhibiting, FGF-2 activity in one or both of the dermis and epidermis.
- FGF-2 activity is promoted.
- FGF-2 activity can be promoted, e.g., by administration of exogenous FGF-2 or a fragment thereof, or a peptide or non-peptide analog thereof.
- FGF-2 activity can also be promoted by administering a nucleic acid which encodes FGF-2 or a fragment thereof, or a peptide analog thereof, or by promoting endogenous FGF-2 activity.
- FGF-2 activity is inhibited.
- FGF-2 activity can be inhibited, e.g., by: administration of an FGF-2 binding molecule, e.g., an anti-FGF-2 antibody or FGF-2 binding fragment thereof, or an FGF-2 binding fragment of the FGF- 2 receptor; administering a compound which inhibits, e.g., competitively or noncompetitively, the binding of FGF-2 to its receptor, e.g., a fragment of FGF-2 which binds the receptor but which lacks biological, e.g., signal transduction, activity, a peptide or non-peptide analog or a small molecule mimic of FGF-2 which binds the receptor but which lacks biological, e.g., signal transduction, activity; administering a nucleic acid which encodes an antisense molecule which inhibits FGF-2 expression.
- an FGF-2 binding molecule e.g., an anti-FGF-2 antibody or FGF-2 binding fragment thereof, or an FGF-2 binding fragment of
- the method is practiced in vivo and the subject is a vertebrate, e.g., a bird, or a mammal, e.g., a rodent, e.g., a mouse or a rat, or a primate, e.g., a nonhuman primate or a human.
- the subject is other than any of a bird, a rodent, e.g., a mouse or a rat, or a nonhuman primate.
- the method is performed in vivo and: the subject is wild type for one or more loci which condition the development of cutaneous appendages, e.g., the subject is wildtype for the scaleless locus; the subject is heterozygous, hemizygous, or homozygous, for a mutation at one or more loci which condition the development of cutaneous appendages, e.g., the subject carries one or more mutant alleles of the scaleless locus; the subject is a transgenic animal which is heterozygous, hemizygous, or homozygous, for a mutation at one or more loci which condition the development of cutaneous appendages, e.g., the subject carries one or more mutant alleles of the scaleless locus.
- the method is practiced in vitro, e.g.. on a tissue or cell, e.g., a cultured cell.
- a compound which modulates FGF-2 activity is administered at least once and preferably at least 2, 4, or 10 times.
- the period between administrations can be more than 2, 4, 10 or 30 days but less than 1 year.
- FGF-2 activity is modulated, e.g., increased or decreased, in the dermis.
- the dermis or epidermis is: fetal dermis or epidermis; adult dermis or epidermis.
- the invention features, a method for promoting development of a cutaneous appendage, e.g., a hair, a scale, or a feather, in a tissue or subject, the method including administering a therapeutically effective amount of exogenous FGF-2 or fragment thereof to the tissue or subject.
- the subject is a vertebrate, e.g., a bird, or a mammal, e.g., a rodent, e.g., a mouse or a rat, or a primate, e.g., a nonhuman primate or a human.
- the subject is other than any of a bird, a rodent, e.g., a mouse or a rat, or a nonhuman primate.
- the exogenous FGF-2 or a fragment thereof is provided to a subject preferably directly, e.g., locally, as by injection or topical administration to a given site, or systemically, e.g., parenterally or orally.
- the invention features, a method of evaluating a compound for the ability to bind an FGF-2 polypeptide and the ability to modulate an FGF-2/FGFR-1 interaction or otherwise modulate FGF-2 activity.
- the compound can be, e.g., a polypeptide or non-peptide compound, e.g., a naturally occurring ligand of an FGF-2 polypeptide, e.g., an FGFR-1 polypeptide, e.g., a fragment of an FGFR-1 polypeptide.
- the method includes: contacting the compound with the FGF-2 polypeptide; and evaluating the ability of the compound to interact with, e.g., to bind or form a complex with the FGF-2 polypeptide, e.g., the ability of the compound to inhibit an FGF- 2/FGFR-l interaction.
- This method can be performed in vitro, e.g., in a cell free system, or in vivo, e.g., in a two-hybrid interaction trap assay. This method can be used to identify compounds, e.g., fragments or analogs of FGFR-1 , which are agonists or antagonists of FGF-2.
- the method can further include the step of applying the evaluated compound to an animal, tissue, or cell to further evaluate its effect on an epidermal- dermal interaction, or a process or product that results from an epidermal-dermal interaction, e.g., placode formation, dermal condensation formation.
- FGFR-1 induction or the development of a cutaneous appendage, e.g., a hair, a scale, or a feather.
- the invention features, a method of evaluating a first compound, e.g., an FGF-2 polypeptide, for the ability to bind a second compound, e.g., a second polypeptide or non-peptide compound, e.g., a naturally occurring ligand of FGF- 2 polypeptide, e.g., an FGFR-1 , or a fragment thereof.
- the method includes: contacting the first compound with the second compound; and evaluating the ability of the first compound to form a complex with the second compound.
- This method can be performed in vitro, e.g., in a cell free system, or in vivo, e.g., in a two-hybrid interaction trap assay.
- This method can be used to identify compounds, e.g., fragments or analogs of FGF-2, which are agonists or antagonists of FGF-2.
- This method can be used to identify compounds, e.g., fragments or analogs of FGFR- 1 , which are agonists or antagonists of FGF-2.
- the method can further include the step of applying the evaluated compound to an animal, tissue, or cell to further evaluate its effect on an epidermal- dermal interaction, or a process or product that results from an epidermal-dermal interaction, e.g., placode formation, dermal condensation formation, FGFR-1 induction, or the development of a cutaneous appendage, e.g., a hair, a scale, or a feather.
- the invention features a method for evaluating a compound, e.g., for the ability to modulate an interaction, e.g., the ability to inhibit an interaction of an FGF-2 polypeptide, with a second polypeptide, e.g., a polypeptide, e.g., a natural ligand of the FGF-2 polypeptide, e.g., an FGFR-1, or a fragment thereof.
- a compound e.g., for the ability to modulate an interaction, e.g., the ability to inhibit an interaction of an FGF-2 polypeptide, with a second polypeptide, e.g., a polypeptide, e.g., a natural ligand of the FGF-2 polypeptide, e.g., an FGFR-1, or a fragment thereof.
- the method includes the steps of (i) combining the second polypeptide (or preferably a purified preparation thereof), an FGF-2 polypeptide, (or preferably a purified preparation thereof), and a compound, e.g., under conditions wherein in the absence of the compound, the second polypeptide, and the FGF-2 polypeptide, are able to interact, e.g., to bind or form a complex; and (ii) detecting the interaction, e.g., detecting the formation (or dissolution) of a complex which includes the second polypeptide, and the FGF-2 polypeptide.
- a change e.g., a decrease or increase, in the formation of the complex in the presence of a compound (relative to what is seen in the absence of the compound) is indicative of a modulation, e.g., an inhibition or promotion, of the interaction between the second polypeptide, and the FGF-2 polypeptide.
- the second polypeptide, and the FGF-2 polypeptide are combined in a cell-free system and contacted with the compound; the cell-free system is selected from a group consisting of a cell lysate and a reconstituted protein mixture; the FGF-2 polypeptide. and the second polypeptide are simultaneously expressed in a cell, and the cell is contacted with the compound, e.g.
- This method can be used to identify compounds, e.g., fragments or analogs of FGFR-1, which are agonists or antagonists of FGF-2.
- the method can further include the step of applying the evaluated compound to an animal, tissue, or cell to further evaluate its effect on an epidermal-dermal interaction, or a process or product that results from an epidermal- dermal interaction, e.g., placode formation, dermal condensation formation, FGFR-1 induction, or the development of a cutaneous appendage, e.g., a hair, a scale, or a feather.
- a molecule has FGF-2 biological activity if it has one or more of the following properties: (1) it induces an epidermal-dermal interaction, or process or product that results from an epidermal-dermal interaction, e.g., placode formation, dermal condensation formation, FGFR-1 induction, or the development of a cutaneous appendage, e.g., a hair, a scale, or a feather, when applied to sc/sc chick tissue as described herein; (2) it is mitogenic; (3) it binds to the FGFR-1 receptor; (4) it is an antagonist or agonist of one or more of the properties described above.
- FGF-2 has been identified as an early ectodermal signal in the epithelial-mesenchymal interactions that occur during feather development. The observation that this growth factor can rescue the mutant phenotype of sc/sc embryos that lack epidermal placodes suggests that FGF-2 is, or is downstream from, the signal that the mutant ectoderm fails to generate. Transcription of FGF-2
- FGF-2 mRNA could be detected in the feather germs at the very edge of the tract where the formation of epidermal placodes precedes the formation of dermal condensations (Sengel, P. Morphogenesis of Skin. Cambridge University Press, Cambridge, England (1976)).
- Cross sections of stained embryos indicate that FGF-2 mRNA expression is restricted to the epidermal placodes of the feather germs.
- spatially FGF-2 expression is restricted to the epidermal placodes and temporally FGF-2 expression precedes the formation of the dermal condensations.
- FGF-2 mRNA was seen in the distal part of the elongating buds. As feather buds grow out into feather filaments, the entire length of the filament expresses FGF-2.
- FGF-2 RNA probe was made using the full-length cDNA for alt-FGF-2 (Zuniga, A. Mejia, B., Meijers, C. and Zeller, R. Dev. Biol. 157:1 10-1 18 (1993)).
- Ectoderm signaling involves FGF-2 Since FGF-2 transcripts are restricted to the ectodermal placodes of normal feather germs and these structures are absent from sc/sc skins, it was hypothesized that the defective signaling in the mutant ectoderm may involve FGF-2.
- exogenous FGF-2 was applied to skins obtained from the dorsal tract of eight day old sc/sc embryos. Heparin beads loaded with FGF-2 were placed on skins supported on millipore filer chambers and cultured on the chorioallantoic membrane of 10 day old chick embryos for three or five days.
- feather buds correlated with feather buds not correlated beads with beads central region 83% (89 buds) 17% (18 buds) lateral region 95% (36 buds) 5% (4 buds)
- Cross sections of feathers in skins cultured for 5 days show normally arranged barb ridges and barbule cells indicating that they are normally developed feathers.
- the length of the feathers is relatively uniform but their size and shape can be irregular. Such irregularities are never observed in normal feathers.
- Most of the abnormal feathers seem to result from fusion of feather buds that can be seen at three days to be located close to each other. Fusions can occur such that the feather filaments have separate bases or tips. The latter type of fusion can result in fork-like structures.
- Another form of abnormal filament involves fusions in the middle of two filaments with separate bases and tips.
- a cross sectional view of one of these fused feathers indicates that the fused feathers are outlined by one feather sheath but a septum divides the structures inside into two separate groups.
- FGF-2 which is expressed in the epidermal placode of feather germs in normal embryos can induce the outgrowth of feathers in sc/sc skins that lack epidermal placodes.
- the identification of FGF-2 as an ectodermal signal in feather development is similar to its role n the limb where FGF-2 and FGF-4 can substitute for the apical ectodermal ridge in limb outgrowth (Fallon, J.F. Lopez, A. Ross, M.A., Savage, M.P., Olwin, B.O.
- FGFR-1 probe was derived from a chick cDNA clone (Pasquale, E.G. and Singer, J.S. Proc. Natl. Acad. Sci., USA 86:5449-5454 (1989)). The RNA probe was a 490 bp fragment encoding the 5' end and the first irnmunoglobulin-like domain of FGFR-1. Induction of Feathers bv FGF-2
- Feathers develop when such foot ectoderm is recombined with dorsal mesoderm (Rawles, M.E., J. Embryol. Exp. Morph. 1 1 :765-789 (1963)). Eight day sc/sc dermis can participate with normal ectoderm in feather formation, but this ability is gradually lost from mutant mesoderm of increasing developmental ages (Noveen, A., Jiang, T-X, Ting-Berreth, S.A. and Chuong, C-M., J. Invest. Derm. 104:71 1-719 (1995)).
- the scaleless mutation affects the ectoderm of the mutant skins in such a way that the normal sequence of tissue interactions is interrupted. It is not clear if an early dermal signal cannot be received by the ectoderm or if the ectoderm cannot respond to that signal.
- the mutant mesoderm is fully capable of participating in feather and scale development when recombined with genetically normal ectoderm (Goetinck, P.F. and Abbott, U.K. J. Exp. Zool. 154:7-19 (1963), Sengel, P. and Abbott, U.K., J. Hered. 54:254-262 (1963), Song, H.-K. and Sawyer, R.H., Dev. Dyn. In Press (1995)).
- FGF-2 signaling is sufficient to form dermal condensations and this signaling is direct
- FGF-2 fibroblast growth factor-2
- FGFR-1 fibroblast growth factor receptor
- FGF-2 Treatment of sc/sc skins with FGF-2 results in the formation of feathers at the site of application of the growth factor and the induced feathers express FGFR-1 in their dermal condensations. From these the role of FGF-2 as an epidermal signal in early feather germ formation was established. The observation that FGF-2 can rescue the mutant phenotype of sc/sc embryos suggests that FGF-2 either is, or is downstream, from the signal that the sc/sc mutant ectoderm fails to generate.
- the rescue data could be interpreted to mean either that the FGF-2 signal acts directly on the mesoderm to form dermal condensations or, alternatively, that the FGF-2 treatment initiates a series of reciprocal interactions between the mesoderm and the ectoderm before the ectoderm instructs the mesoderm to form dermal condensations.
- FGF-2 signaling is sufficient to form dermal condensations and this signaling is direct.
- Formulations and Methods for Administering FGF-2 The FGF-2, FGF-2 fragment or analog may be provided to a subject by any suitable means, preferably directly (e.g., locally, as by injection or topical administration to a tissue locus) or systemically (e.g., parenterally or orally).
- the compound of the invention preferably comprises part of an aqueous solution.
- the solution is physiologically acceptable so that in addition to delivery of the desired compound of the invention to the subject, the solution does not otherwise adversely affect the subjects' electrolyte and volume balance.
- the aqueous medium for the FGF-2 or a fragment thereof thus may comprise normal physiologic saline (9.85% NaCl, 0.15M), pH 7-7.4).
- Useful solutions for parenteral administration may be prepared by any of the methods well known in the pharmaceutical art, described, for example, in Remington's Pharmaceutical Science (Gennaro, A., ed.), Mack Pub., 1990.
- Formulations may include, for example, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, hydrogenated naphthalenes, and the like.
- Formulations for direct administration in particular, may include glycerol and other compositions of high viscosity to help maintain the compound of the invention at the desired locus.
- Biocompatible, preferably bioresorbable, polymers including for example, hyaluronic acid, collagen, tricalcium phosphate, polybutyrate, lactide and glycolide polymers, and lactide/glycolide copolymers, may be useful excipients to control the release of the compound of the invention in vivo.
- Other potentially useful parenteral delivery systems for the compound of the invention include ethylenevinyl acetate copolymer particles, osmotic pumps. implantable infusion system, and liposome.
- Formulations for inhalation administration contain as excipients, for example, lactose, or may be aqueous solutions containing, for example, polyoxyethylene-9- laurly ether, glycocholate and deoxycholate.
- Formulations for topical administration to the skin surface may be prepared by dispersing the compound of the invention with a dermally acceptable carrier such as a lotion, cream, ointment or soap. Particularly useful are carriers capable of forming a film or layer over the skin to localize application and inhibit removal. Production of Fragments and Analogs
- an epidermal-dermal interaction can be modulated by modulating, e.g., promoting or inhibiting, the activity of FGF-2.
- modulating e.g., promoting or inhibiting
- one skilled in the art can alter the FGF-2 structure, e.g., by producing fragments or analogs, and test the newly produced structures for activity. Examples of prior art methods which allow the production and testing of fragments and analogs are discussed below.
- These, or analogous methods can be used to make and screen fragments and analogs of an FGF-2 polypeptide, which bind FGFR- 1.
- these methods can be used to make fragments and analogs of FGF-2 polypeptide ligands, e.g., FGFR-1 , which bind an FGF-2 polypeptide.
- Fragments of a protein can be produced in several ways, e.g., recombinantly, by proteolytic digestion, or by chemical synthesis. Internal or terminal fragments of a polypeptide can be generated by removing one or more nucleotides from one end (for a terminal fragment) or both ends (for an internal fragment) of a nucleic acid which encodes the polypeptide. Expression of the mutagenized DNA produces polypeptide fragments. Digestion with "end-nibbling" endonucleases can thus generate DNA's which encode an array of fragments. DNA's which encode fragments of a protein can also be generated by random shearing, restriction digestion or a combination of the above-discussed methods.
- Fragments can also be chemically synthesized using techniques known in the art such as conventional Merrifield solid phase f-Moc or t-Boc chemistry.
- peptides of the present invention may be arbitrarily divided into fragments of desired length with no overlap of the fragments, or divided into overlapping fragments of a desired length.
- Amino acid sequence variants of a protein can be prepared by random mutagenesis of DNA which encodes a protein or a particular domain or region of a protein. Useful methods include PCR mutagenesis and saturation mutagenesis. A library of random amino acid sequence variants can also be generated by the synthesis of a set of degenerate oligonucleotide sequences. (Methods for screening proteins in a library of variants are elsewhere herein.) PCR Mutagenesis
- PCR mutagenesis reduced Taq polymerase fidelity is used to introduce random mutations into a cloned fragment of DNA (Leung et al., 1989, Technique 1 :11- 15). This is a very powerful and relatively rapid method of introducing random mutations.
- the DNA region to be mutagenized is amplified using the polymerase chain reaction (PCR) under conditions that reduce the fidelity of DNA synthesis by Taq DNA polymerase, e.g., by using a dGTP/dATP ratio of five and adding Mn 2+ to the PCR reaction.
- the pool of amplified DNA fragments are inserted into appropriate cloning vectors to provide random mutant libraries.
- Saturation mutagenesis allows for the rapid introduction of a large number of single base substitutions into cloned DNA fragments (Mayers et al., 1985, Science 229:242). This technique includes generation of mutations, e.g., by chemical treatment or irradiation of single-stranded DNA in vitro, and synthesis of a complimentary DNA strand.
- the mutation frequency can be modulated by modulating the severity of the treatment, and essentially all possible base substitutions can be obtained. Because this procedure does not involve a genetic selection for mutant fragments both neutral substitutions, as well as those that alter function, are obtained. The distribution of point mutations is not biased toward conserved sequence elements.
- a library of homologs can also be generated from a set of degenerate oligonucleotide sequences. Chemical synthesis of a degenerate sequences can be carried out in an automatic DNA synthesizer, and the synthetic genes then ligated into an appropriate expression vector. The synthesis of degenerate oligonucleotides is known in the art (see for example, Narang, SA (1983) Tetrahedron 39:3; Itakura et al. (1981) Recombinant DNA, Proc 3rd Cleveland Sympos. Macromolecules, ed. AG Walton,
- Non-random or directed, mutagenesis techniques can be used to provide specific sequences or mutations in specific regions. These techniques can be used to create variants which include, e.g., deletions, insertions, or substitutions, of residues of the known amino acid sequence of a protein.
- the sites for mutation can be modified individually or in series, e.g., by (1) substituting first with conserved amino acids and then with more radical choices depending upon results achieved, (2) deleting the target residue, or (3) inserting residues of the same or a different class adjacent to the located site, or combinations of options 1-3.
- Alanine scanning mutagenesis is a useful method for identification of certain residues or regions of the desired protein that are preferred locations or domains for mutagenesis, Cunningham and Wells (Science 244:1081-1085, 1989).
- a residue or group of target residues are identified (e.g., charged residues such as Arg, Asp, His, Lys, and Glu) and replaced by a neutral or negatively charged amino acid (most preferably alanine or " polyalanine).
- Replacement of an amino acid can affect the interaction of the amino acids with the surrounding aqueous environment in or outside the cell.
- Those domains demonstrating functional sensitivity to the substitutions are then refined by introducing further or other variants at or for the sites of substitution.
- the site for introducing an amino acid sequence variation is predetermined, the nature of the mutation per se need not be predetermined.
- alanine scanning or random mutagenesis may be conducted at the target codon or region and the expressed desired protein subunit variants are screened for the optimal combination of desired activity.
- Oligonucleotide-mediated mutagenesis is a useful method for preparing substitution, deletion, and insertion variants of DNA, see, e.g., Adelman et al., (DNA 2:183, 1983). Briefly, the desired DNA is altered by hybridizing an oligonucleotide encoding TL mutation to a DNA template, where the template is the single-stranded form of a plasmid or bacteriophage containing the unaltered or native DNA sequence of the desired protein. After hybridization, a DNA polymerase is used to synthesize an entire second complementary strand of the template that will thus incorporate the oligonucleotide primer, and will code for the selected alteration in the desired protein DNA.
- oligonucleotides of at least 25 nucleotides in length are used.
- An optimal oligonucleotide will have 12 to 15 nucleotides that are completely complementary to the template on either side of the nucleotide(s) coding for the mutation. This ensures that the oligonucleotide will hybridize properly to the single- stranded DNA template molecule.
- the oligonucleotides are readily synthesized using techniques known in the art such as that described by Crea et al. (Proc. Natl. Acad. Sci. USA, 75: 5765[1978]).
- the starting material is a plasmid (or other vector) which includes the protein subunit DNA to be mutated.
- the codon(s) in the protein subunit DNA to be mutated are identified.
- a double-stranded oligonucleotide encoding the sequence of the DNA between the restriction sites but containing the desired mutation(s) is synthesized using standard procedures. The two strands are synthesized separately and then hybridized together using standard techniques.
- This double-stranded oligonucleotide is referred to as the cassette.
- This cassette is designed to have 3' and 5' ends that are comparable with the ends of the linearized plasmid, such that it can be directly Hgated to the plasmid.
- This plasmid now contains the mutated desired protein subunit DNA sequence.
- Combinatorial Mutagenesis Combinatorial mutagenesis can also be used to generate mutants.
- the amino acid sequences for a group of homologs or other related proteins are aligned, preferably to promote the highest homology possible. All of the amino acids which appear at a given position of the aligned sequences can be selected to create a degenerate set of combinatorial sequences.
- the variegated library of variants is generated by combinatorial mutagenesis at the nucleic acid level, and is encoded by a variegated gene library.
- a mixture of synthetic oligonucleotides can be enzymatically Hgated into gene sequences such that the degenerate set of potential sequences are expressible as individual peptides, or alternatively, as a set of larger fusion proteins containing the set of degenerate sequences.
- Techniques for screening large gene libraries often include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the genes under conditions in which detection of a desired activity, e.g., in this case, binding to FGF-2 or FGFR-1, facilitates relatively easy isolation of the vector encoding the gene whose product was detected.
- detection of a desired activity e.g., in this case, binding to FGF-2 or FGFR-1
- Each of the techniques described below is amenable to high through-put analysis for screening large numbers of sequences created, e.g., by random mutagenesis techniques.
- Two hybrid assays such as the system described above (as with the other screening methods described herein), can be used to identify fragments or analogs of an FGF-2 polypeptide which binds to the intracellular domain of FGFR-1. These may include agonists, superagonists, and antagonists. (The FGFR-1 domain is used as the bait protein and the library of variants of the FGF-2 are expressed as fish fusion proteins.)
- a two hybrid assay (as with the other screening methods described herein), can be used to find fragments and analogs of FGFR-1 which bind an FGF-2 polypeptide.
- the candidate peptides are displayed on the surface of a cell or viral particle, and the ability of particular cells or viral particles to bind an appropriate receptor protein via the displayed product is detected in a "panning assay".
- the gene library can be cloned into the gene for a surface membrane protein of a bacterial cell, and the resulting fusion protein detected by panning (Ladner et al., WO 88/06630; Fuchs et al. (1991) Bio/Technology 9:1370-1371; and Goward et al. (1992) TIBS 18:136-140).
- a detectably labeled ligand can be used to score for potentially functional peptide homologs.
- Fluorescently labeled ligands e.g., receptors
- fluorescently labeled ligands allows cells to be visually inspected and separated under a fluorescence microscope, or, where the morphology of the cell permits, to be separated by a fluorescence-activated cell sorter.
- a gene library can be expressed as a fusion protein on the surface of a viral particle.
- foreign peptide sequences can be expressed on the surface of infectious phage, thereby conferring two significant benefits.
- coli filamentous phages Ml 3, fd., and fl are most often used in phage display libraries. Either of the phage gill or gVIII coat proteins can be used to generate fusion proteins without disrupting the ultimate packaging of the viral particle.
- Foreign epitopes can be expressed at the NH 2 - terminal end of pill and phage bearing such epitopes recovered from a large excess of phage lacking this epitope (Ladner et al. PCT publication WO 90/02909; Garrard et al., PCT publication WO 92/09690; Marks et al. (1992) J. Biol. Chem. 267:16007-16010; Griffiths et al. (1993) EMBO J 12:725-734; Clackson et al. (1991 ) Nature 352:624-628; and Barbas et al. (1992) PNAS 89:4457-4461).
- E. coli the outer membrane protein, LamB
- LamB the outer membrane protein
- Oligonucleotides have been inserted into plasmids encoding the LamB gene to produce peptides fused into one of the extracellular loops of the protein. These peptides are available for binding to ligands, e.g., to antibodies, and can elicit an immune response when the cells are administered to animals.
- Other cell surface proteins e.g., OmpA (Schorr et al. (1991) Vaccines 91, pp. 387-392), PhoE (Agterberg, et al.
- Peptides can be fused to pilin, a protein which polymerizes to form the pilus-a conduit for interbacterial exchange of genetic information (Thiry et al. (1989) Appl. Environ. Microbiol. 55, 984-993). Because of its role in interacting with other cells, the pilus provides a useful support for the presentation of peptides to the extracellular environment.
- Another large surface structure used for peptide display is the bacterial motive organ, the flagellum.
- Fusion of peptides to the subunit protein flagellin offers a dense array of may peptides copies on the host cells (Kuwajima et al. (1988) Bio/Tech. 6, 1080-1083).
- Surface proteins of other bacterial species have also served as peptide fusion partners. Examples include the Staphylococcus protein A and the outer membrane protease IgA of Neisseria (Hansson et al. ( 1992) J Bacteriol. 174, 4239-4245 and Klauser et al. ( 1990) EMBO J. 9, 1991 - 1999).
- the physical link between the peptide and its encoding DNA occurs by the containment of the DNA within a particle (cell or phage) that carries the peptide on its surface.
- An alternative scheme uses the DNA-binding protein La to form a link between peptide and DNA (Cull et al. (1992) PNAS USA 89:1865-1869).
- This system uses a plasmid containing the Lad gene with an oligonucleotide cloning site at its 3'-end. Under the controlled induction by arabinose, a Lad-peptide fusion protein is produced. This fusion retains the natural ability of Lad to bind to a short DNA sequence known as LacO operator (LacO). By installing two copies of LacO on the expression plasmid, the Lad-peptide fusion binds tightly to the plasmid that encoded it.
- LacO LacO operator
- the plasmids in each cell contain only a single oligonucleotide sequence and each cell expresses only a single peptide sequence, the peptides become specifically and stably associated with the DNA sequence that directed its synthesis.
- the cells of the library are gently lysed and the peptide-DNA complexes are exposed to a matrix of immobilized receptor to recover the complexes containing active peptides.
- the associated plasmid DNA is then reintroduced into cells for amplification and DNA sequencing to determine the identity of the peptide ligands.
- peptides-on-plasmids differs in two important ways from the phage display methods.
- the peptides are attached to the C-terminus of the fusion protein, resulting in the display of the library members as peptides having free carboxy termini.
- Both of the filamentous phage coat proteins, pill and pVIII are anchored to the phage through their C-termini, and the guest peptides are placed into the outward-extending N-terminal domains.
- the phage- displayed peptides are presented right at the amino terminus of the fusion protein.
- a second difference is the set of biological biases affecting the population of peptides actually present in the libraries.
- the Lad fusion molecules are confined to the cytoplasm of the host cells.
- the phage coat fusions are exposed briefly to the cytoplasm during translation but are rapidly secreted through the inner membrane into the periplasmic compartment. remaining anchored in the membrane by their C-terminal hydrophobic domains, with the N-termini, containing the peptides, protruding into the periplasm while awaiting assembly into phage particles.
- the peptides in the Lad and phage libraries may differ significantly as a result of their exposure to different proteolytic activities.
- the phage coat proteins require transport across the inner membrane and signal peptidase processing as a prelude to incorporation into phage.
- Certain peptides exert a deleterious effect on these processes and are underrepresented in the libraries (Gallop et al. (1994) J. Med. Chem. 37(9): 1233-1251 ). These particular biases are not a factor in the La display system.
- the polysomes are sufficiently robust to be affinity purified on immobilized receptors in much the same way as the more conventional recombinant peptide display libraries are screened.
- RNA from the bound complexes is recovered, converted to cDNA, and amplified by PCR to produce a template for the next round of synthesis and screening.
- the polysome display method can be coupled to the phage display system. Following several rounds of screening, cDNA from the enriched pool of polysomes was cloned into a phagemid vector. This vector serves as both a peptide expression vector, displaying peptides fused to the coat proteins, and as a DNA sequencing vector for peptide identification.
- polysome-derived peptides on phage By expressing the polysome-derived peptides on phage, one can either continue the affinity selection procedure in this format or assay the peptides on individual clones for binding activity in a phage ELISA, or for binding specificity in a completion phage ELISA (Barret, et al. (1992) Anal. Biochem 204,357-364). To identify the sequences of the active peptides one sequences the DNA produced by the phagemid host.
- Secondary Screens The high through-put assays described above can be followed by secondary screens in order to identify further biological activities which will, e.g., allow one skilled in the art to differentiate agonists from antagonists.
- the type of a secondary screen used will depend on the desired activity that needs to be tested.
- an assay can be developed in which the ability to inhibit an interaction between a protein of interest and its respective ligand can be used to identify antagonists from a group of peptide fragments isolated though one of the primary screens described above.
- FGF-2 polypeptides to generate mimetics, e.g. peptide or non-peptide agents.
- the peptide mimetics are able to disrupt binding of an FGF-2 to it's counter ligand, e.g., in the case of a FGF-2 polypeptide binding to a naturally occurring ligand, e.g., an FGFR- 1.
- the invention also includes mimetics of an FGFR-1 peptide which block binding of FGFR-1 to FGF-2.
- the critical residues of a subject FGF-2 polypeptide which are involved in molecular recognition of an FGFR-1 polypeptide can be determined and used to generate FGF-2-derived peptidomimetics which competitively or noncompetitively inhibit binding of the FGF-2 with an FGFR-1 polypeptide (see, for example, "Peptide inhibitors of human papillomavirus protein binding to retinoblastoma gene protein" European patent applications EP-412,762A and EP-B31 ,080A).
- scanning mutagenesis can be used to map the amino acid residues of a particular FGF-2 polypeptide involved in binding an FGFR-1 polypeptide
- peptidomimetic compounds e.g. diazepine or isoquinoline derivatives
- Non-hydrolyzable peptide analogs of critical residues can be generated using benzodiazepine (e.g., see Freidinger et al. in Peptides: Chemistry and Biology, G.R.
- the present invention provides assays which can be used to screen for drugs which are either agonists or antagonists of the normal cellular function, in this case, of the FGF-2 polypeptides, or of their role in epidermal-dermal interactions.
- the assay evaluates the ability of a compound to modulate binding between an FGF-2 polypeptide and a naturally occurring ligand, e.g., an FGFR-1.
- a variety of assay formats will suffice and, in light of the present inventions, will be comprehended by skilled artisan.
- Peptide analogs of an FGF-2 polypeptide are preferably less than 150, 130, 1 10, 90, 70 amino acids in length, preferably less than 50 amino acids in length, most preferably less than 30, 20 or 10 amino acids in length. In preferred embodiments, the peptide analogs of an FGF-2 polypeptide are at least about 10, 20, 30, 50 or 100 amino acids in length.
- Peptide analogs of an FGF-2 polypeptide have preferably at least about 50%, 60%, 80%, 85%, 90%, 95% or 99% homology or sequence similarity with the naturally occurring FGF-2 polypeptide.
- Peptide analogs of an FGF-2 polypeptide differ from the naturally occurring FGF-2 polypeptide by at least 1, 2, 5, 10 or 20 amino acid residues; preferably, however, they differ in less than 15, 10 or 5 amino acid residues from the naturally occurring FGF-2 polypeptide.
- Useful analogs of an FGF-2 polypeptide can be agonists or antagonists.
- Antagonists of an FGF-2 polypeptide can be molecules which bind the receptor, e.g., the FGFR-1 receptor, but which lack some additional biological activity such as signal transduction.
- Antagonists can inhibit an epidermal-dermal interaction, or a process or product that results from an epidermal-dermal interaction, e.g., placode formation, dermal condensation formation, FGFR-1 induction, or the development of a cutaneous appendage, e.g., a hair, a scale, or a feather.
- Agonists are derivatives which can promote an epidermal-dermal interaction, or a process or product that results from an epidermal- dermal interaction, e.g., placode formation, dermal condensation formation, FGFR-1 induction, or the development of a cutaneous appendage, e.g., a hair, a scale, or a feather.
- each of the four cysteines present at amino acid residues 26, 70, 88, and 93 of the mature protein of human fibroblast growth factor 2 (FGF-2) was individually changed to serine (Seno et al., "Stabilizing Basic Fibroblast Growth Factor Using Protein Engineering,” in Biochemical and Biophysical Research Communications. (1988), Vol. 151(2):701-708).
- the biological activity and heparin binding ability was retained when the serine was substituted for the cysteine residue at either 70 or 88 of the FGF-2 protein. This finding indicates that the cysteines at these positions are not essential for expressing biological activity.
- FGF-2 human fibroblast growth factor 2
- Structural analogs of human fibroblast growth factor 2 have been prepared by side-directed mutagenesis of a synthetic FGF-2 gene to examine the effect of amino acid substitutions in the three putative heparin-binding domains on FGF's biological activity.
- Heath et al. (1991) Biochemistry 30:5608-5615 discloses a number of such analogs. After expression in Escherichia coli, the mutant proteins were purified to homogeneity by use of heparin-Sepharose chromatography and analyzed for their ability to stimulate DNA synthesis in human foreskin fibroblasts.
- replacement of either arginine- 107 in the second domain or glutamine- 123 in the third domain with glutamic acid resulted in compounds that were 2 and 4 times more potent than FGF-2.
- the hydrophobic contacts dominate the primary binding interaction and provide ⁇ 75% of the binding affinity.
- the secondary FGFR binding site on FGF-2 has an ⁇ 250-fold lower affinity and is composed of amino acids Lys- 110, Tyr-111, and Trp-114 in a surface-exposed to type I ⁇ -turn (formerly known as the putative receptor binding loop).
- cyteines at residues 26, 70, 88 and 93 of the mature FGF-2 play a role in formation of disulfide bonds that induce heterologous conformations.
- Residues Asp- 19, Arg- 107 and Glu- 123 seem to play a role in heparin binding, while residues Tyr-24, Tyr- 103, Leu- 140, Met- 142, Arg-44 and Asn-101 play a role in receptor binding.
- the residues at positions 107 and 109-1 14 seem to have little effect on receptor binding affinities of FGF-2, while Glu-96 is a crucial residue for binding to FGFR-1.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP53733697A JP2001519765A (en) | 1996-04-18 | 1997-04-17 | Regulation of epithelial-mesenchymal interaction |
EP97920411A EP0991422A1 (en) | 1996-04-18 | 1997-04-17 | Modulating epithelial-mesenchymal interactions |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1556096P | 1996-04-18 | 1996-04-18 | |
US60/015,560 | 1996-04-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997038708A1 true WO1997038708A1 (en) | 1997-10-23 |
Family
ID=21772126
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/006309 WO1997038708A1 (en) | 1996-04-18 | 1997-04-17 | Modulating epithelial-mesenchymal interactions |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0991422A1 (en) |
JP (1) | JP2001519765A (en) |
WO (1) | WO1997038708A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1164838A2 (en) * | 1999-02-04 | 2002-01-02 | YEDA RESEARCH AND DEVELOPMENT CO., Ltd. | Screening assay for antagonists of fgfr-mediated malignant cell transformation and tumor formation |
JP2002293720A (en) * | 2001-03-30 | 2002-10-09 | National Institute Of Advanced Industrial & Technology | Hair growth agent |
WO2004056865A2 (en) * | 2002-12-20 | 2004-07-08 | Enkam Pharmaceuticals A/S | Method of modulation of interaction between receptor and ligand |
WO2005047314A2 (en) * | 2003-11-06 | 2005-05-26 | Genencor International, Inc. | Fgf-beta binding and supported peptides |
EP2735303A1 (en) * | 2012-11-23 | 2014-05-28 | Pilosciences | Hair growth compositions and methods |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0543424A (en) * | 1991-08-14 | 1993-02-23 | Sansho Seiyaku Co Ltd | External agent for use in hair |
JPH0640858A (en) * | 1991-09-27 | 1994-02-15 | Shiseido Co Ltd | Hair tonic |
-
1997
- 1997-04-17 JP JP53733697A patent/JP2001519765A/en active Pending
- 1997-04-17 EP EP97920411A patent/EP0991422A1/en not_active Withdrawn
- 1997-04-17 WO PCT/US1997/006309 patent/WO1997038708A1/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0543424A (en) * | 1991-08-14 | 1993-02-23 | Sansho Seiyaku Co Ltd | External agent for use in hair |
JPH0640858A (en) * | 1991-09-27 | 1994-02-15 | Shiseido Co Ltd | Hair tonic |
Non-Patent Citations (2)
Title |
---|
DEVELOPMENTAL BIOLOGY, 1993, Volume 156, DU CROS D.L., "Fibroblast Growth Factor Influences the Development and Cycling of Murine Hair Follicles", pages 444-453. * |
JOURNAL OF INVESTIGATIVE DERMATOLOGY, July 1993, Volume 101, Number 1, (Supplement), DU CROS D.L., "Fibroblast Growth Factor and Epidermal Growth Factor in Hair Development", pages 106S-113S. * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1164838A2 (en) * | 1999-02-04 | 2002-01-02 | YEDA RESEARCH AND DEVELOPMENT CO., Ltd. | Screening assay for antagonists of fgfr-mediated malignant cell transformation and tumor formation |
EP1164838A4 (en) * | 1999-02-04 | 2002-06-19 | Yeda Res & Dev | Screening assay for antagonists of fgfr-mediated malignant cell transformation and tumor formation |
JP2002293720A (en) * | 2001-03-30 | 2002-10-09 | National Institute Of Advanced Industrial & Technology | Hair growth agent |
WO2004056865A2 (en) * | 2002-12-20 | 2004-07-08 | Enkam Pharmaceuticals A/S | Method of modulation of interaction between receptor and ligand |
WO2004056865A3 (en) * | 2002-12-20 | 2005-02-24 | Enkam Pharmaceuticals As | Method of modulation of interaction between receptor and ligand |
US7951906B2 (en) | 2002-12-20 | 2011-05-31 | Enkam Pharmaceuticals A/S | Compounds capable of interacting with a cell-surface fibroblast growth factor receptor |
WO2005047314A2 (en) * | 2003-11-06 | 2005-05-26 | Genencor International, Inc. | Fgf-beta binding and supported peptides |
WO2005047314A3 (en) * | 2003-11-06 | 2006-04-20 | Genencor Int | Fgf-beta binding and supported peptides |
US7485618B2 (en) | 2003-11-06 | 2009-02-03 | Genencor International, Inc. | FGF-5 supported and binding peptides |
EP2735303A1 (en) * | 2012-11-23 | 2014-05-28 | Pilosciences | Hair growth compositions and methods |
WO2014080015A3 (en) * | 2012-11-23 | 2014-07-24 | Pilosciences | Hair growth compositions and methods |
Also Published As
Publication number | Publication date |
---|---|
EP0991422A1 (en) | 2000-04-12 |
JP2001519765A (en) | 2001-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7175842B2 (en) | Methods of modulating hair growth | |
KR100631766B1 (en) | Polypeptides, cDNAs encoding the polypeptides and uses thereof | |
JP4767983B2 (en) | TGFβ1-responsive cells derived from bone marrow | |
AU3961499A (en) | Polynucleotides isolated from skin cells and methods for their use | |
JP2002520068A (en) | Bone morphogenetic protein | |
US7144997B2 (en) | Vertebrate embryonic patterning-inducing proteins, compositions and uses related therto | |
WO2001090357A1 (en) | Compositions isolated from skin cells and methods for their use | |
JP2008526263A (en) | Polynucleotide encoding stem cell factor-like protein | |
JP3966819B2 (en) | Novel second keratinocyte growth factor analogue present in the hair follicle | |
JP2002543824A (en) | Compositions isolated from skin cells and uses thereof | |
US8075894B2 (en) | Use of soluble CD164 in inflammatory and/or autoimmune disorders | |
JP2003526674A (en) | Use of bombesin receptor 3 | |
WO1997038708A1 (en) | Modulating epithelial-mesenchymal interactions | |
AU760252B2 (en) | Modulation of cell proliferation, methods and reagents | |
JP2001509382A (en) | Frazzled nucleotide sequences, expression products, compositions and uses | |
KR100692226B1 (en) | NOVEL POLYPEPTIDES, cDNAS ENCODING THE SAME AND UTILIZATION THEREOF | |
KR101721733B1 (en) | Peptide for promoting angiogenic activity and use thereof | |
JP2002538787A (en) | New compound | |
KR100885545B1 (en) | A polypeptide inhibiting RANK, pharmaceutical composition comprising the same, method of inhibiting osteoclast differentiation, a method of treating or preventing a disease caused by differentiation or activation of osteoclast, nucleic acid encoding the polypeptide, vector comprising the nucleic acid and a host cell transformed with the vector | |
JP2002539826A (en) | New compound | |
KR20010043090A (en) | NOVEL POLYPEPTIDE, cDNA ENCODING THE SAME AND UTILIZATION THEREOF | |
JP2000508908A (en) | Secreted proteins and polynucleotides encoding them | |
JP2004123679A (en) | Composition containing eosinophilic leukocyte cationic protein | |
JPH08504760A (en) | Novel protein tyrosine kinase | |
JP2002516573A (en) | 207 human secreted proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1997 537336 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997920411 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 97537336 Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 97537336 Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1997537336 Format of ref document f/p: F |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1997537336 Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1997920411 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997920411 Country of ref document: EP |